STOCK TITAN

Ligand (LGND) director Nancy Ryan Gray receives new RSUs and options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Ligand Pharmaceuticals director Nancy Ryan Gray received new equity awards. She was granted 836 restricted stock units of common stock, which fully vest on the earlier of the next annual stockholder meeting or the first anniversary of the June 5, 2026 grant date.

Gray was also granted a non-qualified stock option for 2,938 shares of common stock at an exercise price of $237.00 per share, expiring on June 5, 2036. Following these grants, she holds 8,930 shares of common stock directly and 2,938 outstanding stock options.

Positive

  • None.

Negative

  • None.
Insider Gray Nancy Ryan
Role null
Type Security Shares Price Value
Grant/Award Non-Qualified Stock Option (right to buy) 2,938 $0.00 --
Grant/Award Common Stock 836 $0.00 --
Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 2,938 shares (Direct, null); Common Stock — 8,930 shares (Direct, null)
Footnotes (1)
  1. Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
RSUs granted 836 units Restricted stock units granted June 5, 2026
Option shares granted 2,938 shares Non-qualified stock option granted June 5, 2026
Option exercise price $237.00 per share Non-qualified stock option strike price
Option expiration June 5, 2036 Non-qualified stock option expiry date
Shares held after grant 8,930 shares Common stock directly held following awards
Options held after grant 2,938 options Non-qualified options outstanding after grant
restricted stock units financial
"Represents restricted stock units ("RSUs"). Each RSU represents a contingent right"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
RSUs financial
"Represents restricted stock units ("RSUs"). Each RSU represents a contingent right"
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
Non-Qualified Stock Option financial
"Non-Qualified Stock Option (right to buy)"
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
Board of Directors financial
"Acquired by a grant of the Board of Directors of the Company"
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.
annual meeting financial
"grant of the Board of Directors of the Company at their annual meeting"
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gray Nancy Ryan

(Last)(First)(Middle)
555 HERITAGE DRIVE
SUITE 200

(Street)
JUPITER FLORIDA 33458

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
LIGAND PHARMACEUTICALS INC [ LGND ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/05/2026A836(1)A$0.08,930D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Non-Qualified Stock Option (right to buy)$23706/05/2026A2,938 (2)06/05/2036Common Stock2,938$0.02,938D
Explanation of Responses:
1. Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
2. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
By: /s/ Andrew Reardon, Attorney-in-Fact For: Nancy Ryan Gray06/09/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Nancy Ryan Gray acquire in this Ligand (LGND) Form 4 filing?

Nancy Ryan Gray received 836 restricted stock units and a non-qualified stock option for 2,938 shares at $237.00 per share. These equity awards were granted as director compensation at the June 5, 2026 annual meeting.

How do the RSUs granted to Nancy Ryan Gray at Ligand (LGND) vest?

The 836 restricted stock units fully vest on the earlier of the next Ligand annual stockholder meeting or the first anniversary of the June 5, 2026 grant date. Each RSU converts into one share of Ligand common stock upon vesting.

What are the key terms of Nancy Ryan Gray’s stock option grant at Ligand (LGND)?

Nancy Ryan Gray received a non-qualified stock option for 2,938 shares of Ligand common stock with a $237.00 exercise price. The option was granted June 5, 2026 and expires on June 5, 2036, providing long-term potential equity exposure.

How many Ligand (LGND) shares does Nancy Ryan Gray hold after these awards?

After the June 5, 2026 equity awards, Nancy Ryan Gray directly holds 8,930 shares of Ligand common stock. She also holds a non-qualified stock option covering 2,938 additional shares, separate from her existing direct share position.

Is Nancy Ryan Gray’s Ligand (LGND) Form 4 a purchase or an award?

The Form 4 reports compensation-related awards, not open-market purchases. Nancy Ryan Gray acquired 836 restricted stock units and an option for 2,938 shares, both granted by Ligand’s Board of Directors as part of her service as a director.